Standard opioid-containing versus opioid-sparing anesthesia on early postoperative recovery after video-assisted thoracic surgery: A propensity-weighted analysis

Yan-yu Jiang1,2, Zhen-ping Li2, Ming Yao2 and Qing-he Zhou2,3*

1Graduate School, Bengbu Medical College, Bengbu, China, 2Graduate School, Bengbu Medical College, Bengbu, China, 3Department of Anesthesiology and Pain Medicine, The Affiliated Hospital of Jiaxing University, Jiaxing, China

Purpose: Opioids have several adverse effects. At present, there are no large clinical studies on the effects of opioid-sparing anesthesia on early postoperative recovery after thoracoscopic surgery. This study was to investigate the effects of opioid-sparing anesthesia on early postoperative recovery after thoracoscopic surgery.

Methods: Adult patients who underwent video-assisted thoracic surgery from 1 January 2019 to 28 February 2021 were enrolled by reviewing the electronic medical records. Participants were divided into opioid-sparing anesthesia (OSA group) and opioid-containing anesthesia (STD group) based on intraoperative opioid usage. The propensity-score analysis was to compare the early postoperative recovery of two groups. The outcome measurements included the incidence of postoperative nausea and vomiting (PONV) during an entire hospital stay, need for rescue antiemetic medication, postoperative-pain episodes within 48 h after surgery, need for rescue analgesia 48 h postoperatively, duration of postoperative hospital stay, length of PACU stay, postoperative fever, postoperative shivering, postoperative atrial fibrillation, postoperative pulmonary infection, postoperative hypoalbuminemia, postoperative hypoxemia, intraoperative blood loss, and intraoperative urine output.

Results: A total of 1,975 patients were identified. No significant difference was observed in patient characteristics between the OSA and STD groups after adjusting for propensity score-based inverse probability treatment weighting. The incidence of postoperative nausea and vomiting was significantly lower in the OSA group than in the STD group (14.7% vs. 18.9%, p = 0.041). The rescue antiemetic use rate was lower in the OSA group than in the STD group (7.5% vs.12.2%; p = 0.002). PACU duration was longer in the OSA group than in the STD group (70.8 ± 29.0 min vs. 67.3 ± 22.7 min; p = 0.016). The incidence of postoperative fever was higher in the STD group than that in the OSA group (11.0% vs.7.7%; p = 0.032). There were no differences between the groups in terms of other outcomes.

Conclusions: Our results suggest that opioid-sparing anesthesia has a lower incidence of postoperative complications than opioid-based anesthetic techniques.

Keywords: opioid-sparing anesthesia, video-assisted thoracic surgery, postoperative nausea and vomiting, inverse probability treatment weighting, postoperative recovery
Introduction

Opioids are often used during the perioperative period for intraoperative analgesia and postoperative pain management. Since the 1960s, opioids have become an indispensable component of modern anesthesia (1). Notwithstanding, the routine use of opioids during anesthesia has recently been interrogated. They have well-known short-term and potential long-term adverse effects on patients and society (2). Opioid-related adverse effects can manifest as a multitude of postoperative symptoms, ranging from postoperative nausea and vomiting (PONV), respiratory depression, delirium, and ileus to hyperalgesia (3). Hyperalgesia is a paradoxical phenomenon observed with sensitization of the nervous system that exacerbated painful responses to noxious stimulation (4). These adverse effects seem to accumulate as patients take opioids for longer periods after surgery (5).

Owing to the side effects of opioids, opioid-free anesthesia has recently attracted interest from anesthesiologists. In essence, opioid-free anesthesia is the practice of intraoperative anesthesia without opioid use (6). Several studies have investigated opioid-free anesthesia, which has proven feasible in many surgeries, including laparoscopic, gynecological, chest, and heart surgeries (7–9). Nonetheless, in a recent study, Beloeil et al. (10) noted that more patients under opioid-free anesthesia with dexmedetomidine experienced severe adverse events. Therefore, opioid-sparing anesthesia (OSA) is an alternative option. OSA achieves intraoperative analgesia by administering a minimal amount of opioid analgesics combined with non-opioid adjuvants during surgery (11). The current basis for reducing opioid use in the perioperative setting is a multimodal analgesia regimen comprising non-opioid anesthetics and regional anesthetic techniques (12). Using these methods, the anesthesiologist can take advantage of the multiple mechanisms of different pharmacological agents that potentially collaborate to achieve hypnosis, autonomic stability, weakening of sympathetic responses, and intraoperative and postoperative analgesia (13).

To date, no study has comprehensively reported OSA in video-assisted thoracic surgery. Moreover, in our hospital, a lot of thoracic surgeries have made use of OSA with dexmedetomidine. Hence, this study aimed to comparatively assess the effects of standard opioid-containing and opioid-sparing anesthetic techniques on early postoperative recovery after video-assisted thoracic surgery, using propensity-weighted analysis.

Methods

Study design and inclusion criteria

This single-center, retrospective study was approved by the Ethics Committee of the Affiliated Hospital of Jiaxing University (Jiaxing, China; No. 2021–410), which waived the requirement for written informed consent. The study enrolled adult patients consecutively who underwent video-assisted thoracic surgery from 1 January 2019 to 28 February 2021 by reviewing the electronic medical records at our hospital.

Exclusion criteria

The exclusion criteria included (1) patients who had motion sickness, (2) patients who underwent other concurrent operations, (3) patients who underwent intraoperative thoracotomy conversion, and (4) patients taking opioids chronically prior to surgery.

Grouping

All included patients were further categorized into two groups based on whether they continued the addition of opioids intraoperatively. In patients receiving OSA (OSA group), dexmedetomidine was used for intra-analgesia in patients in whom opioid addition was discontinued. In our study, we defined the group that continued receiving remifentanil during surgery as the opioid-based anesthetic technique group (STD group). All data were obtained from the Haitai electronic medical record system and Docare anesthesia clinical information system. Two investigators reviewed all data and conducted a consistency check after collection. Data were collected and analyzed privately with a specific identification number for each patient.

Intraoperative and postoperative care

All patients underwent general anesthesia. Before anesthesia, patients were routinely monitored using electrocardiography, blood pressure measurement, and oxygen saturation monitoring. Patients underwent continuous radial artery puncture manometry before surgery if they had a normal Allen-test result. The Bispectral Index™ (BIS™) was used to adjust the depth of anesthesia to maintain the BIS between 40 and 60. The anesthesia program complied with the medication specifications of the anesthesiology department of the affiliated hospital of Jiaxing University. Based on ideal body weight, both groups of patients were induced to receive sufentanil or fentanyl (0.3–0.5 µg/kg or 3–5 µg/kg; Yichang Humanwell Pharmaceutical Co, Ltd, China), propofol 1–2.5 mg/kg, etomidate 0.15–0.3 mg/kg, cis-atracurium 0.15–0.2 mg/kg, or rocuronium bromide 0.6–1 mg/kg. Continuous inhalation of sevoflurane was administered after induction. Cis-atracurium was discontinuously added to maintain muscle relaxation as required. In the OSA group, the depths of anesthesia and
analgesia were maintained using propofol (3–12 mg/kg/h) and dexmedetomidine (0.2–0.7 µg/kg/h). In the STD group, anesthesia was maintained using remifentanil (0.1–0.2 µg/kg/min; Yichang Humanwell Pharmaceutical Co., Ltd, China) and compounded with propofol (3–12 mg/kg/h). In both groups, the change in intraoperative anesthesia-related drug dosage was determined by the anesthesiologist in charge of the patient. In general, hemodynamic stability is maintained by adjusting the depth of anesthesia. In cases where the intraoperative mean arterial pressure was 30% lower than the baseline or systolic pressure <90 mmHg, an intravenous infusion of 6 mg ephedrine was rapidly administered. If the intraoperative mean arterial pressure was 30% higher than the baseline, 10 mg of urapidil was administered. During surgery, esmolol was used to treat tachycardia (heart rate >110 beats/min) during intubation and intraoperatively. If the patient’s heart rate was <50 beats/min or excessive salivary-gland secretion occurred, atropine (0.5 mg) was administered.

All patients were intubated with a double-lumen tube (Covidien LLC, China) using fiber-optic bronchoscope positioning and ventilated with the following parameter during one-lung ventilation: tidal volume of 6–8 ml/kg. The tracheal model was selected according to the height and diameter of the trachea in the chest computed tomography scan: 37 Fr/Ch (12.3 mm) was selected for men and 35 Fr/Ch (11.7 mm) for women. The ventilator parameters were adjusted to maintain the end-tidal carbon dioxide between 35 and 45 mmHg. During the procedure, all patients received 3 mg of granisetron. The length of hospital stay was recorded from the end of the surgery to the time of discharge.

Data collection

We reviewed the patients’ electronic medical records and collected their demographic characteristics, including age, sex, body mass index, and American Society of Anesthesiologists (ASA) physical status. We also collected data on potential risk factors that potentially affect outcomes, including coexistent disease (hypertension, diabetes, cardiovascular diseases, cerebrovascular disease, respiratory system diseases, and/or depression), surgery type (pulmonary wedge, pulmonary lobectomy, segmentectomy, pulmonary bulla resection, the number of trochal ports, mediastinal tumor resection, thymectomy, or thoracic sympatheticectomy), smoking status, anesthesia-induction drugs, anesthesia-maintenance drugs, other intraoperative drugs, perioperative nerve block, analgesic pump, surgical duration, duration of anesthesia, duration of mechanical ventilation, and amount of rehydration. These variables constituted the baseline indicators in our study.

Outcomes

Endpoints that occurred during hospitalization were obtained from the inpatient electronic medical records. The primary outcome measure was the incidence of PONV during the entire hospital stay. We also investigated several other pre-specified secondary outcomes: the need for rescue antiemetic medication, postoperative-pain episodes (defined as any episode with an NRS >3) within 48 h after surgery, need for rescue analgesia 48 h postoperatively, duration of postoperative hospital stay, length of PACU stay, postoperative fever, postoperative shivering, postoperative atrial fibrillation, postoperative pulmonary infection, postoperative hypoalbuninemia, postoperative hypoxemia, intraoperative blood loss, and intraoperative urine output. The pain was measured using NRS scores, ranging from 0 to 10, and postoperative hypoxemia was defined as a SpO2 level <95% with a need for oxygen supplementation.

Statistical analysis

Continuous variables are described as means ± standard deviations for normally distributed variables, medians and
interquartile ranges [IQRs] for non-normally distributed variables, and frequencies and percentages for categorical variables. Between-group differences were reported using the independent samples t-test, chi-square ($\chi^2$) test, or nonparametric test, as appropriate, and the 95% confidence interval (CI) was calculated. Missing continuous variables were replaced by the median. In the current study, remifentanil administration was at the discretion of the attending anesthetist and was not randomly assigned to the subjects. To reduce bias in comparing non-randomized treatments, we calculated the propensity score for each subject. The propensity score is defined as the probability of treatment assignment conditional on the measured baseline covariates. In our study, the propensity score was the probability of receiving remifentanil and was estimated using a logistic regression model. To control for confounding factors in case of an unknown relationship between the groups (OSA and STD) and covariates, we used inverse probability treatment weighting (IPTW) using generalized boosted models or multivariate nonparametric regression techniques. IPTW weights were estimated as the inverse values of patients’ estimated probability of belonging to the OSA group. IPTW, based on propensity scores, was used to balance the distributions of the collected baseline variables in the OSA and STD groups (16). On applying IPTW, baseline variables were considered balanced between the OSA and STD groups if the absolute standardized mean difference was <0.1. All reported p values were two-sided, and values of $p < 0.05$ were considered statistically significant. All analyses were performed using R (version 4.1.2; the R Foundation for Statistical Computing, http://www.r-project.org).

Results

Patient characteristics

A total of 1,975 patients were included in the present study (STD group, $n = 681$, 34.5%; OSA group, $n = 1294$, 65.5%). During induction, all patients received opioids comprising a sufentanil dose of 30 [30–30] μg (sufentanil and fentanyl are converted according to sufentanil: fentanyl = 10 μg: 0.1 mg, and all are expressed with sufentanil). In the STD group, remifentanil was administered at a dose of 450 [300–630] μg. In the OSA group, dexmedetomidine was administered at a dose of 40 [30–53] μg. Weighting by the inverse of the propensity score eliminated baseline-variable imbalances to produce a high degree of balance for these variables between the two groups. We compared baseline patient characteristics before and after weighting, and the results are shown in Table 1. Weighting reduced standardized differences for all observed covariates below 10% in absolute value, demonstrating substantial improvement in covariate balance across the treatment groups (Figure 1).

Postoperative outcomes after weighting

Approximately 16.5% (326/1975) of patients developed PONV during hospitalization. The PONV rate was significantly lower in the OSA group than in the STD group after weighting (14.7% vs.18.9%; $p = 0.041$), and there was a significant decrease in the use of rescue antiemetics in the OSA group (7.5% vs. 12.2%; $p = 0.002$). PACU duration was longer in the OSA group than in the STD group (70.8 ± 29.0 vs. 67.3 ± 22.7; $p = 0.016$). The incidence of postoperative fever was higher in the STD group than that in the OSA group (11.0% vs. 7.7%; $p = 0.032$). There were no differences in the number of cases with NRS scores >3, hospital length of stay, and postoperative rescue analgesia. No differences were found in the incidence of postoperative urinary retention, postoperative shivering, postoperative atrial fibrillation, postoperative pulmonary infection, postoperative hypalbuminemia, and postoperative hypoxemia between the two groups (Table 2).

Operative outcomes after weighting

Intraoperative blood loss and urine output did not differ between the STD and OSA groups ($p > 0.05$) (Table 2). Intraoperative atropine use was lower in the STD group ($p < 0.05$); however, there was no significant difference in the intraoperative use of esmolol, ephedrine, and norepinephrine between the two groups ($p > 0.05$) (Table 3).

Discussion

In this retrospective study, we compared the effects of standard opioid-containing anesthesia with those of OSA on postoperative recovery after video-assisted thoracic surgery using propensity score-based IPTW. Our findings demonstrated that OSA was associated with a decrease in PONV, a reduction in postoperative remedial antiemetic incidence, and a decrease in postoperative fever, while the duration of PACU stays in patients under OSA was prolonged.

A large number of patients experience PONV after general anesthesia (17–19). The application of opioids in the perioperative period is one of the major reasons for this phenomenon (20–22). Previous studies have reported conflicting results regarding the effect of remifentanil on PONV. In a small randomized controlled trial, Watanabe et al. (23) reported that remifentanil was rapidly excreted and did not affect the incidence of PONV. However, a
| Variables                          | Before IPTW     | p-value | After IPTW     | p-value |
|-----------------------------------|----------------|---------|----------------|---------|
| **Group STD, n = 681**            |                |         | **Group OSA, n = 1294** |         |
| Age [mean (SD); years]            | 57.5 ± 13.2    | 0.005   | 57.0 ± 13.3    | 0.786   |
| Male/female, no.                  | 252/429        | 0.388   | 506/788        | 0.781   |
| BMI [mean (SD); kg/m²]            | 23.4 ± 3.3     | 0.153   | 23.3 ± 3.1     | 0.923   |
| **Group STD, n = 489.86a**        |                |         | **Group OSA, n = 489.57a** |         |
| History of smoking, no. (%)       | 658 (96.6%)    | 0.081   | 144 (11.1%)    | 0.880   |
| Hemoglobin [mean (SD); g/L]       | 136.9 ± 15.2   | 0.113   | 136.9 ± 15.3   | 0.749   |
| Hypertension, no. (%)             | 220 (32.3%)    | 0.159   | 149.2 (30.5%)  | 0.943   |
| Diabetes, no. (%)                 | 62 (9.1%)      | 0.362   | 42.6 (8.7%)    | 0.965   |
| Cerebrovascular disease, no. (%)  | 12 (1.7%)      | 0.391   | 10.1 (2.1%)    | 0.891   |
| Cardiovascular diseases, no. (%)  | 27 (4.0%)      | 1       | 21.1 (4.3%)    | 0.857   |
| Respiratory system diseases, no. (%) | 10 (1.5%)    | 0.943   | 7.2 (1.5%)     | 0.794   |
| Depression, no. (%)               | 9 (1.3%)       | 0.802   | 6.0 (1.2%)     | 0.873   |
| Type of surgery                   | 0.003          |         | 0.999          |         |
| Pulmonary wedging, no. (%)        | 188 (27.6%)    | 134.7 (27.5%) | 134.0 (27.4%) |
| Pulmonary lobectomy, no. (%)      | 220 (32.3%)    | 162.7 (33.2%) | 164.8 (33.7%) |
| Pulmonary segmentectomy, no. (%)  | 218 (32.0%)    | 146.4 (29.9%) | 143.9 (29.4%) |
| Pulmonary bulla resection, no. (%)| 17 (2.4%)      | 15.5 (3.2%)   | 15.6 (3.2%)   |         |
| Mediastinal tumor resection, no. (%) | 21 (3.1%)    | 18.0 (3.7%)   | 19.5 (4.0%)   |         |
| Thymectomy, no. (%)               | 17 (2.4%)      | 12.5 (2.6%)   | 11.8 (2.4%)   |         |
| Thoracic sympathectomy, no. (%)   | 0 (0%)         | 0.0 (0.0%)    | 0.0 (0.0%)    |         |
| The number of VATS ports, no. (%) | 315 (46.3%)    | 224.5 (45.9%) | 224.8 (46.0%) |
| Duration of surgery, (min)        | 90 [65–120]    | 97.1 ± 42.9 | 96.8 ± 43.6   | 0.883   |
| Duration of anesthesia, (min)     | 110 [90–145]   | 118.6 ± 43.9 | 118.3 ± 45.1  | 0.913   |
| Duration of mechanical ventilation, (min) | 135 [105–165] | 140.8 ± 45.2 | 140.7 ± 45.9  | 0.936   |
| Crystal liquid, (ml)              | 1000 [500,1000] | 869.0 ± 369.7 | 872.5 ± 377.8 | 0.868   |
| Colloidal fluid, (ml)             | 500 [500,500]  | 422.4 ± 245.8 | 419.6 ± 285.8 | 0.855   |
| Induction of anesthetics          |                |         |                |         |
| Sufentanil (µg)b                  | 30 [25,30]     | 29.1 ± 7.3 | 29.0 ± 5.3    | 0.760   |
| Cis-atracurium, no. (%)           | 590 (86.6%)    | 418.0 (85.3%) | 416.5 (85.1%) | 0.892   |
| Rocuronium bromide, no. (%)       | 91 (13.4%)     | 71.8 (14.7%) | 73.1 (14.9%)  | 0.892   |
| Midazolam, no. (%)                | 123 (18.1%)    | 61.2 (12.5%) | 60.9 (12.4%)  | 0.982   |
| Etomidate, no. (%)                | 570 (83.7%)    | 388.7 (79.3%) | 385.3 (78.7%) | 0.767   |
| Maintenance anesthetics           |                |         |                |         |
| Propofol, no. (%)                 | 592 (86.9%)    | 451.7 (92.2%) | 450.2 (92.0%) | 0.860   |
| Sevoflurane, no. (%)              | 634 (93.8%)    | 457.9 (93.5%) | 458.9 (93.7%) | 0.845   |
| Cis-atracurium, no. (%)           | 418 (61.4%)    | 286.6 (58.5%) | 282.2 (57.6%) | 0.751   |
| Rocuronium bromide, no. (%)       | 9 (1.3%)       | 7.1 (1.4%)  | 8.5 (1.7%)    | 0.692   |
| Other intraoperative drugs        |                |         |                |         |
| Desocine, no. (%)                 | 464 (68.1%)    | 381.0 (77.8%) | 378.7 (77.4%) | 0.860   |

(continued)
TABLE 1 Continued

| Variables                                | Before IPTW | After IPTW |
|------------------------------------------|-------------|------------|
|                                          | Group STD, n = 681 | Group OSA, n = 1294 | p-value |
|                                          |             |             |          |
| Ketorolac tromethamine, no. (%)          | 514 (75.5%) | 938 (72.5%) | 0.168    |
| Parezon, no. (%)                         | 15 (2.2%)   | 25 (1.9%)   | 0.812    |
| Loroxinam, no. (%)                       | 7 (1.0%)    | 23 (1.8%)   | 0.271    |
| Tramadol, no. (%)                        | 1 (0.1%)    | 6 (0.5%)    | 0.467    |
| Fluribiprofen ester, no. (%)             | 53 (7.8%)   | 24 (1.9%)   | <0.001   |
| Butorphanol tartrate, no. (%)            | 71 (10.4%)  | 3 (0.2%)    | <0.001   |
| Dexamethasone, no. (%)                   | 192 (28.2%) | 366 (28.3%) | 1        |
| Postoperative analgesic mode             |             |             | 0.001    |
| PCIA, no. (%)                            | 607 (89.1%) | 1198 (92.6%)| 451.7 (92.2%) |
| PCEA, no. (%)                            | 2 (0.3%)    | 11 (0.9%)   | 2.0 (0.4%) |
| PCNA, no. (%)                            | 3 (0.4%)    | 0 (0%)      | 0.0 (0.0%)|
| Perioperative nerve block                |             | <0.001      | 1        |
| Intercostal nerve blocks, no. (%)        | 591 (86.8%) | 1258 (97.2%)| 465.8 (95.1%) |
| SAP, no. (%)                             | 31 (4.6%)   | 6 (0.5%)    | 6.6 (1.3%) |
| TPVB, no. (%)                            | 34 (5.0%)   | 10 (0.8%)   | 7.1 (1.4%) |
| PECS, no. (%)                            | 12 (1.8%)   | 4 (0.3%)    | 3.7 (0.8%) |
| ESPN, no. (%)                            | 10 (1.5%)   | 5 (0.4%)    | 4.8 (1.0%) |
| Epidural anesthesia, no. (%)             | 3 (0.4%)    | 11 (0.9%)   | 2.0 (0.4%) |

aThe number of subjects changed after IPTW in the calculation; however, the actual number of subjects did not change.

bSufentanil and fentanyl are converted according to sufentanil: fentanyl = 10µg: 0.1 mg, and all are expressed with sufentanil; cerebrovascular disease including cerebral infarction; cardiovascular diseases including coronary heart disease, arrhythmia, heart failure; respiratory system diseases including chronic obstructive pulmonary disease, asthma, bronchitis, bronchiectasis.

The data are presented as means ± SD for continuous variables and frequency (%) for categorical variables. IPTW, inverse probability of treatment weighting; BMI, body mass index; ASA, American Society of Anesthesiologists; PCEA, patient controlled epidural analgesia; PCIA, patient controlled intravenous analgesia; PCNA, patient controlled nerve analgesia; SAP, serratus anterior plane block; TPVB, thoracic paravertebral block; PECS, pectoral nerves block; ESPB, Erector spinae plane block.

A retrospective study performed on 423 patients who underwent elective mastectomy under general anesthesia reported the incidence of PONV with remifentanil to be similar to that with other opioids and may be highly correlated with the dose of remifentanil (24). In our study, patients who underwent OSA exhibited a lower incidence of PONV, and the frequency of postoperative rescue-antiemetic use was also significantly reduced. The correlation between the intraoperative dosage of remifentanil and PONV warrants further confirmation by a well-designed, prospective, large-sample trial.

The difference in PACU duration between the two groups was notable yet not surprising. In the current study, patients with opioid-free anesthesia increased the use of dexmedetomidine. Although many factors affect the duration of PACU, in this study, we think that the main reason for the longer PACU duration is that the half-life of dexmedetomidine is significantly longer than that of remifentanil (25). Recently, Devine et al. (26) conducted a case-control study to investigate opioid-free anesthesia for lung cancer resection. In that study, PACU duration in patients under opioid-free anesthesia was also longer than that under standard opioid-containing anesthesia, which is consistent with our study’s results. Arguably, an OSA technique embracing a multimodal analgesic regimen may contribute to reductions in PONV and, if present, potentially prolong PACU duration to a certain extent.

There were no differences in postoperative pain scores and use of rescue analgesia within 48 h after surgery. Several studies have suggested that the intraoperative pumping of remifentanil increases the use of postoperative analgesics (10, 27). High-dose remifentanil use was associated with higher postoperative pain scores and opioid consumption. This phenomenon is most likely due to the development of acute opioid tolerance (28). In the current study, we combined other analgesics, such as NSAIDs and sevoflurane, with remifentanil; thus, the dosage of remifentanil was less than that in the abovementioned report (10).

Perhaps the unexpected finding of the current study was that patients under OSA exhibited a lower probability of fever than those under standard opioid-containing anesthesia. Dexmedetomidine reduces central sympathetic nerve activity, which potentially inhibits the production of...
It is likely that the anti-inflammatory effect of dexmedetomidine potentially benefits patients with fever (31). However, no difference in postoperative lung infection was found between the two groups. The cause of lung infection is multifactorial and may be influenced by other factors, such as the external environment and care factors. Other outcomes, such as postoperative hypoxemia, postoperative urinary retention, and length of hospital stay, did not differ significantly between the two groups.

In the present study, we also compared the application of intraoperative vasoactive drugs and found that patients administered standard opioid-containing drugs were more likely to use atropine than patients administered OSA. Dexmedetomidine, a selective α2-adrenoceptor agonist, tends to lower heart rate (32). A previous study demonstrated that heart rate decreased transiently soon after the initiation of remifentanil infusion (33). Considering that patients were in a lateral position during surgery, the surgical use of atropine is not exclusively for the purpose of raising heart rate but also to reduce oral secretion (34). Thus, the difference in atropine use between the two groups may be related to reducing oral secretion. Differences in the use of ephedrine, esmolol, and deoxygenation were not statistically significant between the two groups, indicating that the hemodynamic fluctuations of the two groups were similar.

Our study has certain limitations. First, because of the retrospective nature of the study, undiscovered confounding factors might have remained, despite the use of propensity-score analytics. However, such confounders would need to be very significant to invalidate the results of this study. Second, due to the large number of baseline indicators included in the present study, many baseline indicators, such as auxiliary drugs used in anesthesia, were considered categorical variables, and no quantitative analysis was performed. Third, the results revealed that OSA was associated with a decreasing PONV incidence. PONV was not recorded in the medical record system according to a four-point scale (35). Therefore,
we could not analyze the severity of postoperative nausea and vomiting in both patient groups.

Conclusions

We found OSA to be associated with decreases in PONV, postoperative remedial antiemetic use, and postoperative fever incidence after video-assisted thoracic surgery. However, the findings of our study, which were based on a non-randomized design, warrant similar analyses using larger sample sizes, prospective follow-up studies, and confirmation in randomized clinical trials.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of the Affiliated Hospital of Jiaxing University (Jiaxing, China; No. 2021–410). The ethics committee waived the requirement of written informed consent for participation.

TABLE 2: Outcome analyses.

| Outcome                                      | Before IPTW |   |   |   | After IPTW |   |   |   |
|----------------------------------------------|-------------|---|---|---|------------|---|---|---|
|                                              | Group STD, n = 681 | Group OSA, n = 1294 | p-value | Group STD, n = 489.86 | Group OSA, n = 489.57 | p-value |
| PONV, no. (%)                                | 132 (19.4%) | 196 (15.1%) | 0.019 | 92.5 (18.9%) | 72.2 (14.7%) | 0.041 |
| Use of rescue antiemetic, no. (%)            | 87 (12.8%) | 101 (7.8%) | <0.001 | 59.9 (12.2%) | 36.5 (7.5%) | 0.002 |
| Postoperative urinary retention, no. (%)     | 5 (0.7%) | 7 (0.5%) | 0.825 | 4.6 (0.9%) | 2.5 (0.5%) | 0.361 |
| Postoperative fever, no. (%)                 | 74 (10.9%) | 108 (8.3%) | 0.079 | 53.9 (11.0%) | 37.5 (7.7%) | 0.032 |
| Postoperative shiver, no. (%)                | 12 (1.8%) | 9 (0.7%) | 0.049 | 7.0 (1.4%) | 5.2 (1.1%) | 0.544 |
| Postoperative atrial fibrillation, no. (%)   | 28 (4.1%) | 70 (5.4%) | 0.249 | 19.1 (3.9%) | 29.6 (6.1%) | 0.083 |
| Postoperative pulmonary infection, no. (%)   | 82 (12.0%) | 205 (15.8%) | 0.027 | 61.6 (12.6%) | 79.9 (16.3%) | 0.058 |
| Postoperative hypalbuminemia, no. (%)        | 11 (1.6%) | 19 (1.5%) | 0.952 | 8.5 (1.7%) | 8.7 (1.8%) | 0.958 |
| Postoperative hypoxemia, no. (%)             | 22 (3.2%) | 32 (2.5%) | 0.403 | 13.8 (2.8%) | 12.4 (2.5%) | 0.744 |
| Number of episodes with NRS > 3, no. (%)     | 42 (6.2%) | 55 (4.3%) | 0.078 | 27.7 (5.7%) | 23.5 (4.8%) | 0.496 |
| Hospital LOS, (day)                          | 5.9 ± 3.6 | 6.1 ± 3.7 | 0.297 | 6.0 ± 3.7 | 6.2 ± 3.5 | 0.371 |
| PACU LOS, (min)                              | 67.1 ± 22.2 | 72.2 ± 28.9 | <0.001 | 67.3 ± 22.7 | 70.8 ± 29.0 | 0.016 |
| Intraoperative blood loss, (ml)              | 46.3 ± 99.3 | 50.6 ± 110.8 | 0.401 | 45.7 ± 85.5 | 55.9 ± 132.1 | 0.086 |
| Intraoperative urine output, (ml)            | 213.5 ± 192.1 | 216.6 ± 182.7 | 0.731 | 222.5 ± 204.6 | 218.8 ± 180.3 | 0.736 |

Postoperative rescue analgesia in 48 h

| Morphine, no. (%)                             | 18 (2.6%) | 15 (1.2%) | 0.024 | 10.7 (2.2%) | 8.0 (1.6%) | 0.476 |
| Oxycodeone, no. (%)                           | 8 (1.2%) | 25 (1.9%) | 0.288 | 5.9 (1.2%) | 7.7 (1.6%) | 0.572 |
| NSAIDs, no. (%)                               | 32 (4.7%) | 52 (4.0%) | 0.552 | 24.1 (4.9%) | 19.0 (3.9%) | 0.348 |

The number of subjects changed after IPTW in the calculation; however, the actual number of subjects did not change. Categorical variables data are presented as median (25th percentile-75th percentile) and frequency (%). PONV, postoperative nausea and vomiting; NRS, numerical rate scale; LOS, length of stay; PACU, post-anesthesia care unit; NSAIDs, nonsteroidal anti-inflammatory drugs.

TABLE 3: Using of vasoactive drugs during operation.

| Outcome                                      | Before IPTW |   |   |   | After IPTW |   |   |   |
|----------------------------------------------|-------------|---|---|---|------------|---|---|---|
|                                              | Group STD, n = 681 | Group OSA, n = 1294 | p-value | Group STD, n = 489.86 | Group OSA, n = 489.57 | p-value |
| Ephedrine, no. (%)                           | 56 (8.2%) | 140 (10.8%) | 0.079 | 41.9 (8.6%) | 52.2 (10.7%) | 0.200 |
| Densyepinephrine, no. (%)                    | 154 (22.6%) | 203 (15.7%) | <0.001 | 98.1 (20.0%) | 93.8 (19.2%) | 0.690 |
| Atropine, no. (%)                            | 295 (43.3%) | 371 (28.7%) | <0.001 | 187.6 (38.3%) | 147.7 (30.2%) | 0.002 |
| Esmolol, no. (%)                             | 303 (44.5%) | 491 (37.9%) | 0.006 | 179.5 (36.7%) | 177.9 (36.3%) | 0.908 |

The number of subjects changed after IPTW in the calculation; however, the actual number of subjects did not change.
Author contributions

All authors contributed to the study’s conception and design. Material preparation, data collection, and analysis were performed by YyJ, ZpL, MY, and QhZ. The first draft of the manuscript was written by YyJ and all authors commented on previous versions of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by Key Discipline established with Zhejiang Province and Jiaxing City jointly (2019-ss-ttyx).

References

1. Lavand’homme P, Estebe JP. Opioid-free anesthesia: a different regard to anesthesia practice. Curr Opin Anaesthesiol. (2018) 31:556–61. doi: 10.1097/ACO.0000000000000362
2. Shanthanna H, Lalda KS, Khelet H, Joshi GP. Perioperative opioid administration. Anaesthesia. (2021) 134:645–59. doi: 10.1097/ALN.0000000000000372
3. Oderda GM, Senagore AJ, Morland K, Jqbal SU, Kugel M, Liu S, et al. Opioid-related respiratory and gastrointestinal adverse events in patients with acute postoperative pain: prevalence, predictors, and burden. J Pain Palliat Care Pharmacother. (2019) 33:82–97. doi: 10.1016/j.jpcc.2019.1669092
4. Keller DS, Zhang I, Chand M. Opioid-free colorectal surgery: a method to improve patient & financial outcomes in surgery. Surg Endosc. (2019) 33:1959–66. doi: 10.1007/s00464-018-6477-5
5. El-Kefraoui C, Olleik G, Chay MA, Kouyoumdjian A, Nguyen-Powanda P, Rajabiyazdi F, et al. Opioid versus opioid-free analgesia after surgical discharge: protocol for a systematic review and meta-analysis. BMJ Open. (2020) 10:e035443. doi: 10.1136/bmjopen-2019-035443
6. Soffin EM, Wetmore DS, Beckman SH, Shahe EA, Vashnah AS, Albert TJ, et al. Opioid-free anesthesia within an enhanced recovery after surgery pathway for minimally invasive lumbar spine surgery: a retrospective matched cohort study. Neurosurg Focus. (2019) 46:E8. doi: 10.3171/2019.1.FOCUS18645
7. Fiore Jr Jr, Olleik G, El-Kefraoui C, Verdohl B, Kouyoumdjian A, Aldritt A, et al. Preventing opioid prescription after major surgery: a scoping review of opioid-free analgesia. Br J Anaesth. (2019) 123:627–36. doi: 10.1093/bja/aej090
8. Matthies K, Gromski MA, Schinder BE, Spiegel JE. Opioid-free single-incision laparoscopic (SIL) cholecystectomy using bilateral TAP blocks. J Clin Anesth. (2012) 24:65–7. doi: 10.1016/j.claneu.2011.04.014
9. Guinot PG, Spitz A, Berthoud V, Ellouze O, Missaoui A, Constandache T, et al. Effect of opioid-free anaesthesia on post-operative period in cardiac surgery: a retrospective matched case-control study. BMC Anesthesiol. (2019) 19:136. doi: 10.1186/s12871-019-0801-y
10. Beloeil H, Garot M, Lebuffe G, Gerbaud A, Bila J, Cuvillon P, et al. Balanced opioid-free analgesia with dexmedetomidine versus balanced analgesia with remifentanil for major or intermediate noncardiac surgery. Anesthesiology. (2021) 123:S41-S51. doi: 10.1097/ALN.0000000000003723
11. Sui EY, Moon TS. Opioid-free and opioid-sparing anesthesia. Int Anesthesiol Clin. (2020) 58:34–41. doi: 10.1097/AIA.0000000000000270
12. Aarts MA, Rotstein OD, Peersall EA, Victor JC, Okrainec A, McKenzie M, et al. Postoperative ERAS interventions have the greatest impact on optimal recovery experience with implementation of ERAS across multiple hospitals. Ann Surg. (2018) 267:992–7. doi: 10.1097/SLA.0000000000002632
13. Chia PA, Cannesson M, Bui CCM. Opioid free anesthesia feasible? Curr Opin Anaesthesiol. (2020) 33:512–7. doi: 10.1097/ACO.0000000000000878
14. Aldrete JA. The post-anesthesia recovery score revisited. J Clin Anesth. (1995) 7:89–91. doi: 10.1016/0952-8180(94)90001-k
15. Abbott TEF, Fowler AJ, Pelslo P, Gama de Abreu M, Moeller AM, Canet J, et al. A systematic review and consensus definitions for standardised end-points in perioperative medicine: pulmonary complications. Br J Anesth. (2018) 120:1066–79. doi: 10.1093/bja/aeb210
16. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. (2015) 34:3661–79. doi: 10.1002/sim.6607
17. Gan TJ. Postoperative nausea and vomiting can it be eliminated? JAMA. (2002) 287:1233–6. doi: 10.1001/jama.287.10.1233
18. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. (1992) 77:162–84. doi: 10.1097/00000542-199207000-00023
19. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. (2008) 79:213–43. doi: 10.2165/00003495-200805090-00005
20. Frauchenkrt J, Kirkham KR, Jacot-Guillarmod E, Abrrecht E. Analgesic impact of intra-operative opioids vs. Opioid-free anesthesia: a systematic review and meta-analysis. Anesthesia. (2019) 74:651–62. doi: 10.1111/anae.14582
21. De Boer HD, Detriole O, Forger P. Opioid-related side effects: postoperative ileus, urinary retention, nausea and vomiting, and shivering. A review of the literature. Best Pract Res Clin Anaesthesiol. (2017) 31:499–504. doi: 10.1016/j.bpa.2017.07.002
22. Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth. (2012) 109:742–53. doi: 10.1093/bja/aes276
23. Watanabe T, Moriya K, Tsubokawa N, Baba H. Effect of remifentanil on postoperative nausea and vomiting: a randomized pilot study. J Anesth. (2018) 32:781–5. doi: 10.1007/s00540-018-2550-4
24. Horumai J, Egi M, Sugita S, Sato T. Dose of intraoperative remifentanil administration is independently associated with increase in the risk of postoperative nausea and vomiting in elective mastectomy under general anesthesia. J Clin Anesth. (2016) 34:227–31. doi: 10.1016/j.claneu.2016.04.018
25. Lavand’homme P. Opioid-free anaesthesia: pro: damned if you don’t use opioids during surgery. Eur J Anaesthesiol. (2019) 36:247–9. doi: 10.1097/EAJ.0000000000000966
26. Devine G, Cheng M, Martinez G, Patwardhan C, Areus G, Peryt A, et al. Opioid-free anesthesia for lung cancer resection: a case-control study. J Cardiothorac Vasc Anesth. (2020) 34:7036–40. doi: 10.1053/j.jvca.2020.05.022
27. Wu JX, Assel M, Vickers A, Afonso AM, Twersky RS, Simon BA, et al. Impact of intraoperative remifentanil on postoperative pain and opioid use in thyroid surgery. J Surg Oncol. (2019) 120:1456–61. doi: 10.1002/jso.25746

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
28. Yu EH, Tran DH, Lam SW, Irwin MG. Remifentanil tolerance and hyperalgesia: short-term gain, long-term pain? *Anaesthesia*. (2016) 71:1347–62. doi: 10.1111/anae.13602

29. Li B, Li Y, Tian S, Wang H, Wu H, Zhang A, et al. Anti-inflammatory effects of perioperative dexmedetomidine administered as an adjunct to general anesthesia: a meta-analysis. *Sci Rep*. (2015) 5:12342. doi: 10.1038/srep12342

30. Flanders CA, Rocke AS, Edwardson SA, Baillie JK, Walsh TS. The effect of dexmedetomidine and clonidine on the inflammatory response in critical illness: a systematic review of animal and human studies. *Crit Care*. (2019) 23:402. doi: 10.1186/s13054-019-2690-4

31. Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K. Effects of dexmedetomidine on mortality rates and inflammatory responses to endotoxin-induced shock in rats. *Crit Care Med*. (2014) 42:1322–6. doi: 10.1097/01.ccm.0000128579.84228.2a

32. Colin PJ, Hannivoort LN, Eleveld DJ, Reytjens KMEM, Absalom AR, Vereecke HEM, et al. Dexmedetomidine pharmacodynamics in healthy volunteers: 2. Haemodynamic profile. *Br J Anaesth*. (2017) 119:211–20. doi: 10.1093/bja/aex086

33. Shirasaka T, Yano T, Kunitake T, Tsuneyoshi I. High-dose remifentanil increases blood pressure and heart rate mediated by sympathetic activation in conscious rats. *J Anesth*. (2013) 27:325–32. doi: 10.1007/s00540-012-1515-2

34. Candiotti K. A primer on nerve agents: what the emergency responder, anesthesiologist, and intensivist needs to know. *Can J Anaesth*. (2017) 64:1059–70. doi: 10.1007/s12630-017-0920-2

35. Sonner JM, Hynson JM, Clark O, Katz JA. Nausea and vomiting following thyroid and parathyroid surgery. *J Clin Anesth*. (1997) 9:398–402. doi: 10.1016/0952-8180(97)00069-x